This page shows the latest Lyxumia news and features for those working in and with pharma, biotech and healthcare.
European Commission licenses the once-daily version of Lantus and Lyxumia. Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes. ... The dual-drug treatment combines the firm's
Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy
Adlyxin/Lyxumia (lixisenatide).
Sanofi's lixisenatide-only drug Lyxumia has been on the market in Europe since 2013 and was approved in the US by the FDA as Adlyxin in July this year.
Lyxumia (lixisenatide) - helped more patients with type 2 diabetes reach post-prandial glucose targets than Lantus.
Lyxumia (lixisenatide), and has extended its review period by three months.
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Suliqua &Lyxumia/ Adlyxin for Type 2 diabetes. Purchase of. royalty rights.
Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted ... With a single daily injection and only one step to
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.
The appointment comes at crucial time for Zealand, with its diabetes partnership with Sanofi set to pay off as the big pharma company gears up to launch Lyxumia (lixisenatide) this year.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...